TW201613652A - Camptothecin derivative, polymeric compound combined with HSP90 inhibitor, and use thereof - Google Patents

Camptothecin derivative, polymeric compound combined with HSP90 inhibitor, and use thereof

Info

Publication number
TW201613652A
TW201613652A TW104105732A TW104105732A TW201613652A TW 201613652 A TW201613652 A TW 201613652A TW 104105732 A TW104105732 A TW 104105732A TW 104105732 A TW104105732 A TW 104105732A TW 201613652 A TW201613652 A TW 201613652A
Authority
TW
Taiwan
Prior art keywords
ratio
aspartic acid
hsp90 inhibitor
group
polymeric compound
Prior art date
Application number
TW104105732A
Other languages
English (en)
Inventor
Manami Okazaki
Sakiko Maruyama
Akira Masuda
Keiichiro Yamamoto
Original Assignee
Nippon Kayaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Kayaku Kk filed Critical Nippon Kayaku Kk
Publication of TW201613652A publication Critical patent/TW201613652A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/40—Polyamides containing oxygen in the form of ether groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/48—Polymers modified by chemical after-treatment
TW104105732A 2014-02-19 2015-02-17 Camptothecin derivative, polymeric compound combined with HSP90 inhibitor, and use thereof TW201613652A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014029048 2014-02-19

Publications (1)

Publication Number Publication Date
TW201613652A true TW201613652A (en) 2016-04-16

Family

ID=53878146

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104105732A TW201613652A (en) 2014-02-19 2015-02-17 Camptothecin derivative, polymeric compound combined with HSP90 inhibitor, and use thereof

Country Status (3)

Country Link
JP (1) JP6580030B2 (zh)
TW (1) TW201613652A (zh)
WO (1) WO2015125640A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109476841A (zh) * 2016-07-30 2019-03-15 日本化药株式会社 新型高分子衍生物和使用其的新型高分子衍生物成像探针

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108697806A (zh) * 2016-03-01 2018-10-23 日本化药株式会社 含有喜树碱类高分子衍生物的药物制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004039869A1 (ja) * 2002-10-31 2004-05-13 Nippon Kayaku Kabushiki Kaisha カンプトテシン類の高分子誘導体
CA2664852A1 (en) * 2006-10-03 2008-04-10 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of resorcinol derivatives
US20080248097A1 (en) * 2007-02-26 2008-10-09 Kwon Glen S Polymeric micelles for combination drug delivery
CA2853799A1 (en) * 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
EP2836238B1 (en) * 2012-04-12 2018-05-02 Nitto Denko Corporation Co-polymer conjugates
JP6223995B2 (ja) * 2012-11-08 2017-11-01 日本化薬株式会社 カンプトテシン類と抗癌効果増強剤の結合した高分子化合物及びその用途

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109476841A (zh) * 2016-07-30 2019-03-15 日本化药株式会社 新型高分子衍生物和使用其的新型高分子衍生物成像探针
US10869937B2 (en) 2016-07-30 2020-12-22 Nippon Kayaku Kabushiki Kaisha Polymer derivatives, and novel polymer derivative imaging probe using same
CN109476841B (zh) * 2016-07-30 2021-08-24 日本化药株式会社 新型高分子衍生物和使用其的新型高分子衍生物成像探针

Also Published As

Publication number Publication date
JPWO2015125640A1 (ja) 2017-03-30
JP6580030B2 (ja) 2019-09-25
WO2015125640A1 (ja) 2015-08-27

Similar Documents

Publication Publication Date Title
MX2020006168A (es) Compuestos de 4-azaindol.
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
MY172924A (en) Neprilysin inhibitors
MX348422B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
ES2626555T3 (es) Pyridone amides como moduladores de canales de sodio
NZ593110A (en) pteridinone derivatives as MODULATORS OF TOLL-LIKE RECEPTORS
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
GEP20146197B (en) New compounds
PH12013500848A1 (en) Trpv1 antagonists and uses thereof
MY151986A (en) Adamantyl diamide derivatives and uses of same
MD4556C1 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
EA201891179A1 (ru) N-замещенные индольные производные в качестве модуляторов pge2 рецепторов
IN2014CN04530A (zh)
MX345780B (es) Inhibidores triciclicos de girasa.
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
MY186599A (en) Substituted pyridopyrazines as novel syk inhibitors
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
EA201992679A1 (ru) N-замещенные индольные производные
FI20115234A0 (fi) Uusia pyridatsinoni- ja pyridoniyhdisteitä
PH12017500351A1 (en) N-(2-(cyclic amine)ethyl)benzamide derivatives as p2x7 inhibitors
PH12015502429A1 (en) Dicarboxylic acid compound
EA201591175A1 (ru) Трициклические соединения в качестве ингибиторов cftr
PH12014501181A1 (en) N- (4 -quinolinylmethyl) sulfonamide derivatives and their use as anthelmintics